• Sevilay Topcuoglu, Cansev Arslanbuga, Tugba Gursoy, Alev Aktas, Guner Karatekin, Ramazan Uluhan, and Fahri Ovali.
• a Neonatal Intensive Care Unit, Zeynep Kamil Maternity and Children's Training and Research Hospital , Istanbul , Turkey .
• J. Matern. Fetal. Neonatal. Med. 2016 Jan 1; 29 (11): 1834-9.

ObjectiveOne of the most challenging aspects in the management of neonates with late-onset neonatal sepsis (LOS) is to make the diagnosis. Presepsin is a novel and promising marker of sepsis. The aim of this study was to assess the role of presepsin in the diagnosis of LOS in preterm infants.MethodsForty-two premature newborns ≤32 weeks gestational age with a diagnosis of LOS were prospectively involved in the study. Forty gestational and postnatal age-matched infants without sepsis served as controls. Levels of presepsin, C-reactive protein, and procalcitonin were measured at enrollment and on the third and seventh days of sepsis.ResultsInitial presepsin levels in the LOS group were significantly higher than in the control group (1024 pg/mL, min-max: 295-8202; versus 530 pg/mL, min-max: 190-782; p < 0.0001). The area under the receiver-operating curve for presepsin was 0.864. A presepsin value of 800.5 pg/mL was established as a cut-off value, with 67% sensitivity and 100% specificity. Presepsin levels gradually decreased during treatment.ConclusionPresepsin can be used as a reliable biomarker for LOS and treatment response in preterm infants. However, we could not demonstrate the efficacy of presepsin for the detection of disease severity or prognosis.

20 keywords...

hide…